Interleukin-15 in autoimmunity
Copyright © 2020 Elsevier Ltd. All rights reserved..
Interleukin-15 (IL-15) is a member of the IL-2 family of cytokines, which use receptor complexes containing the common gamma (γc) chain for signaling. IL-15 plays important roles in innate and adaptative immune responses and is implicated in the pathogenesis of several immune diseases. The IL-15 receptor consists of 3 subunits namely, the ligand-binding IL-15Rα chain, the β chain (also used by IL-2) and the γc chain. IL-15 uses a unique signaling pathway whereby IL-15 associates with IL-15Rα during biosynthesis, and this complex is 'trans-presented' to responder cells that expresses the IL-2/15Rβγc receptor complex. IL-15 is subject to post-transcriptional and post-translational regulation, and evidence also suggests that IL-15 cis-signaling can occur under certain conditions. IL-15 has been implicated in the pathology of various autoimmune diseases such as rheumatoid arthritis, autoimmune diabetes, inflammatory bowel disease, coeliac disease and psoriasis. Studies with pre-clinical models have shown the beneficial effects of targeting IL-15 signaling in autoimmunity. Unlike therapies targeting other cytokines, anti-IL-15 therapies have not yet been successful in humans. We discuss the complexities of IL-15 signaling in autoimmunity and explore potential immunotherapeutic approaches to target the IL-15 signaling pathway.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2020 |
---|---|
Erschienen: |
2020 |
Enthalten in: |
Zur Gesamtaufnahme - volume:136 |
---|---|
Enthalten in: |
Cytokine - 136(2020) vom: 30. Dez., Seite 155258 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Allard-Chamard, Hugues [VerfasserIn] |
---|
Links: |
---|
Themen: |
Autoimmunity |
---|
Anmerkungen: |
Date Completed 26.11.2021 Date Revised 26.11.2021 published: Print-Electronic Citation Status MEDLINE |
---|
doi: |
10.1016/j.cyto.2020.155258 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM314913858 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM314913858 | ||
003 | DE-627 | ||
005 | 20231225153753.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2020 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1016/j.cyto.2020.155258 |2 doi | |
028 | 5 | 2 | |a pubmed24n1049.xml |
035 | |a (DE-627)NLM314913858 | ||
035 | |a (NLM)32919253 | ||
035 | |a (PII)S1043-4666(20)30274-X | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Allard-Chamard, Hugues |e verfasserin |4 aut | |
245 | 1 | 0 | |a Interleukin-15 in autoimmunity |
264 | 1 | |c 2020 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 26.11.2021 | ||
500 | |a Date Revised 26.11.2021 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a Copyright © 2020 Elsevier Ltd. All rights reserved. | ||
520 | |a Interleukin-15 (IL-15) is a member of the IL-2 family of cytokines, which use receptor complexes containing the common gamma (γc) chain for signaling. IL-15 plays important roles in innate and adaptative immune responses and is implicated in the pathogenesis of several immune diseases. The IL-15 receptor consists of 3 subunits namely, the ligand-binding IL-15Rα chain, the β chain (also used by IL-2) and the γc chain. IL-15 uses a unique signaling pathway whereby IL-15 associates with IL-15Rα during biosynthesis, and this complex is 'trans-presented' to responder cells that expresses the IL-2/15Rβγc receptor complex. IL-15 is subject to post-transcriptional and post-translational regulation, and evidence also suggests that IL-15 cis-signaling can occur under certain conditions. IL-15 has been implicated in the pathology of various autoimmune diseases such as rheumatoid arthritis, autoimmune diabetes, inflammatory bowel disease, coeliac disease and psoriasis. Studies with pre-clinical models have shown the beneficial effects of targeting IL-15 signaling in autoimmunity. Unlike therapies targeting other cytokines, anti-IL-15 therapies have not yet been successful in humans. We discuss the complexities of IL-15 signaling in autoimmunity and explore potential immunotherapeutic approaches to target the IL-15 signaling pathway | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Research Support, Non-U.S. Gov't | |
650 | 4 | |a Review | |
650 | 4 | |a Autoimmunity | |
650 | 4 | |a IL-15 | |
650 | 4 | |a Immunotherapy | |
650 | 4 | |a Rheumatoid arthritis | |
650 | 4 | |a Type 1 diabetes | |
650 | 7 | |a IL15 protein, human |2 NLM | |
650 | 7 | |a Interleukin-15 |2 NLM | |
700 | 1 | |a Mishra, Hemant K |e verfasserin |4 aut | |
700 | 1 | |a Nandi, Madhuparna |e verfasserin |4 aut | |
700 | 1 | |a Mayhue, Marian |e verfasserin |4 aut | |
700 | 1 | |a Menendez, Alfredo |e verfasserin |4 aut | |
700 | 1 | |a Ilangumaran, Subburaj |e verfasserin |4 aut | |
700 | 1 | |a Ramanathan, Sheela |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Cytokine |d 1994 |g 136(2020) vom: 30. Dez., Seite 155258 |w (DE-627)NLM012645575 |x 1096-0023 |7 nnns |
773 | 1 | 8 | |g volume:136 |g year:2020 |g day:30 |g month:12 |g pages:155258 |
856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.cyto.2020.155258 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 136 |j 2020 |b 30 |c 12 |h 155258 |